First human test of new Alpha-1 drug halted after early phase
NCT ID NCT02363946
Summary
This early-stage study tested a new drug called ARC-AAT to see if it was safe and could lower harmful protein levels in people with Alpha-1 Antitrypsin Deficiency, a genetic condition that can damage the lungs and liver. The trial involved 65 healthy volunteers and patients with Alpha-1, who received a single dose of either the drug or a placebo. The main goal was to check for side effects and measure how the drug behaved in the body, but the study was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Melbourne, Victoria, 3004, Australia
-
Research Site 2
Homburg, Germany
-
Research Site 3
Leiden, 2333ZA, Netherlands
-
Research Site 4
Edgbaston, Birmingham, B15 2WB, United Kingdom
Conditions
Explore the condition pages connected to this study.